Fortis Healthcare reported a 17.5% revenue rise to ₹2,545 crore in Q1 FY27, though operating margins were impacted by new ESOP costs and ongoing capacity expansion. While short-term profitability faces pressure, the company remains focused on its long-term goal of achieving 25% EBITDA margins by FY28 through increased facility utilization.
Fortis Healthcare reported a 17.5% year-on-year growth in consolidated revenue to ₹2,545 crore for the first quarter of fiscal year 2027. Despite this strong top-line performance, the company experienced a compression in its profitability metrics, with consolidated operating EBITDA margins settling at 21.1% for the period.
Impact of ESOPs and New Facility Ramp-up
The dip in margins is primarily attributed to two strategic factors: the implementation of a new Employee Stock Option Plan (ESOP) and the costs associated with expanding hospital capacity. The ESOP program, designed to retain talent, resulted in additional quarterly expenses ranging between ₹31 crore and ₹50 crore. Simultaneously, Fortis added 100 new hospital beds during the quarter and continues to invest in scaling up its network.
Newly commissioned hospitals often face a gestation period where operating costs are high relative to revenue. As these facilities, such as those in regions like Manesar and Greater Noida, work to increase patient occupancy and optimize operations, they place temporary pressure on the overall margin profile. The company plans to operationalize an additional 400 beds throughout the remainder of FY27, which may maintain some pressure on margins in the near term.
Debt and Expansion Strategy
As the company pursues its long-term growth trajectory, net debt has risen to ₹2,233 crore, bringing the net debt-to-EBITDA ratio to 1.01x. This spending is part of a broader commitment to add approximately 1,800 beds between FY27 and FY30. While these investments are aimed at capturing future demand, they require careful capital management to balance the debt load with the need for operational scaling.
Path to Margin Recovery
Despite the recent margin compression, management has reaffirmed its long-term guidance of achieving a 25% EBITDA margin by FY28. The company expects this recovery to be driven by the gradual maturity of newer facilities, where increased patient volume and better operational efficiency are expected to improve profitability.
For investors, the key monitorable in the coming quarters will be the pace at which these new facilities reach optimal utilization levels. Tracking the balance between capital spending, debt levels, and the actual delivery of margin expansion will provide clarity on whether the company can successfully navigate the current transition period.